Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.47 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.47 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496662 | 0.87 | KDM4E (0.72) | KDM4EPKMALDH1A1HPGDPTGS2 | |
| SCHEMBL268643 | 0.84 | KDM4E (0.49) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL22256926 | 0.83 | TARBP2 (0.57) | KDM4EPKMALDH1A1HPGDMAPT | |
| SCHEMBL269009 | 0.83 | PIN1 (0.61) | KDM4EALDH1A1HPGDHCRTR1HCRTR2 | |
| SCHEMBL80459 | 0.82 | ALOX5 (0.61) | KDM4EALDH1A1HPGDPTGS2LMNA | |
| SCHEMBL21615580 | 0.82 | PPARD (0.47) | KDM4EPKMHCRTR1HCRTR2 | |
| SCHEMBL270942 | 0.81 | HCRTR1 (0.51) | PTGS2HCRTR1HCRTR2ALOX5 | |
| SCHEMBL269233 | 0.81 | SMN1; SMN2 (0.51) | KDM4EPKMALDH1A1PTGS2HCRTR1 | |
| SCHEMBL925813 | 0.81 | PTGS2 (0.49) | ALDH1A1PTGS2HCRTR1HCRTR2ALOX5 | |
| SCHEMBL17948786 | 0.80 | KDM4E (0.53) | KDM4EPKMALDH1A1HPGDPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040966-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-06-22 | — | — | US | disclosed |
| US-20190263797-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-08-29 | — | — | US | disclosed |
| US-10329287-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-25 | — | — | US | disclosed |
| US-20170305897-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-26 | — | — | US | disclosed |
| US-20170305897-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-26 | — | — | US | disclosed |
| US-9732075-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-15 | — | — | US | disclosed |
| US-9732075-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-15 | — | — | US | disclosed |
| EP-2855453-B1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-07 | — | — | EP | disclosed |
| US-20150166527-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-06-18 | — | — | US | disclosed |
| US-20150166527-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-06-18 | — | — | US | disclosed |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100184808-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100113531-A1 | THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-05-06 | — | — | US | disclosed |
| EP-2164847-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2010-03-24 | — | — | EP | disclosed |
| WO-2010004507-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-01-14 | — | — | WO | disclosed |
| EP-2125760-A2 | THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-12-02 | — | — | EP | disclosed |
| EP-2069332-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009004584-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008117241-A2 | THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008020405-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166527-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | KDM4E 2288/4885PKM 813/4885ALDH1A1 519/4885 |
| US-20100113531-A1 | THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | KDM4E 3188/4885PKM 2881/4885ALDH1A1 680/4885 |
| US-10329287-B2 | Benzimidazole-proline derivatives | HCRTR1, HCRTR2, NPY1R | KDM4E 2320/4885PKM 842/4885ALDH1A1 604/4885 |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | KDM4E 903/4885PKM 4399/4885ALDH1A1 1961/4885 |
| US-11040966-B2 | Benzimidazole-proline derivatives | HCRTR1, HCRTR2, NPY1R | KDM4E 2320/4885PKM 842/4885ALDH1A1 604/4885 |
| US-20100184808-A1 | 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS | HCRTR2, HCRTR1, OXTR | KDM4E 711/4885PKM 4646/4885ALDH1A1 731/4885 |
| US-20190263797-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | KDM4E 2320/4885PKM 842/4885ALDH1A1 604/4885 |
| US-20170305897-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | KDM4E 2320/4885PKM 842/4885ALDH1A1 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.